Naringenin is used for preparing products for preventing and/or treating abdominal aortic aneurysms. The products include drugs and/or health care products. The products were tested in two clinically associated abdominal aortic aneurysm disease models: using angiotensin II (1000 ng/kg/min) through subcutaneous submerging pump to induce ApoE knockout mice; and using calcium phosphate (0.5 M) to daub the abdominal aortas of locally induced C57 mice with abdominal aortic aneurysms. Experiments demonstrate that orally administered naringenin can significantly inhibit the onset and development of an abdominal aortic aneurysm in the CaPO4 daubed and AngII submerging pump induced mice. Thus, naringenin can be used in the treatment of patients with abdominal aortic aneurysms.